🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

10,225 results for “He” Clear

  1. BAX326

    Takeda

    Hemophilia B

    phase 3 mab completed

    1 trial

  2. BAX855

    Takeda

    Hemophilia A

    phase 3 mab completed

    1 trial

  3. BAX855

    Baxalta Innovations GmbH

    Hemophilia A

    phase 3 mab completed

    1 trial

  4. BAY 1841788, TRIPTORELIN

    Ningbo Cancer Hospital

    Patients with localised prostate cancer and high-risk features of relapse (minimum 2 high-risk criteria from National Comprehensive Cancer Network (NCCN) classification)1 and with no detectable metastasis, including no evidence of pelvic lymph node metastasis on next-generation imaging (PSMA PET/CT).

    phase 3 small molecule active

    1 trial

  5. BAY 3427080, BAY 3427080 60 mg capsules placebo

    Bayer AG

    Vasomotor symptoms caused by adjuvant endocrine therapy in women with, or at high risk for developing hormone-receptor positive breast cancer

    phase 3 small molecule active

    1 trial

  6. BAY 59-7939

    Bayer HealthCare AG

    Pulmonary Embolism

    phase 3 small molecule completed

    1 trial

  7. BAY 94-8862, Finerenone, Placebo coated tablet 002 to BAY 948862 coated tablet

    The George Institute

    Chronic kidney disease

    phase 3 small molecule active

    1 trial

  8. BAY94-9027

    Bayer HealthCare AG

    Hemophilia A

    phase 3 mab completed

    1 trial

  9. BCG (Tokyo 172) vaccine

    United Therapeutics Europe Ltd

    Tuberculosis Infection

    phase 3 mab terminated

    1 trial

  10. BCX4161

    Biocryst

    Hereditary Angioedema

    phase 3 small molecule completed

    4 trials

  11. BCX7353

    Biocryst

    Hereditary Angioedema

    phase 3 small molecule completed

    4 trials

  12. BCX7353 capsules

    Biocryst

    Hereditary Angioedema, HAE

    phase 3 small molecule completed

    1 trial

  13. BCX7353 capsules

    Biocryst

    Hereditary Angioedema

    phase 3 small molecule completed

    1 trial

  14. BENDAFOLIN 10 mg/ml Injektionslösung, Irinotecan Bendalis 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, 5-FLUOROURACIL–EBEWE, 50 MG/ML, ROZTWÓR DO WSTRZYKIWAN I INFUZJI, Napabucasin

    The George Institute

    Histologically confirmed adenocarcinoma of the colon or rectum that is metastatic.

    phase 3 small molecule active

    1 trial

  15. BENDAMUSTINE , TOCILIZUMAB , SILTUXIMAB , GEMCITABINE , ANAKINRA , Epcoritamab, DIPHENHYDRAMINE , PARACETAMOL , DEXAMETHASONE , RITUXIMAB , OXALIPLATIN , Epcoritamab

    Genmab A/S

    B-cell Lymphoma

    phase 3 small molecule active

    1 trial

  16. BEP(500)

    United Therapeutics Europe Ltd

    Stage I Testicular Non-Seminomatous Germ Cell Tumor

    phase 3 small molecule completed

    1 trial

  17. BETAMETHASONE, Placebo of fludrocortisone, HYDROCORTISONE HEMISUCCINATE, Placebo of hydrocortisone, FLUDROCORTISONE

    Pari Pharma GmbH

    Patients admitted to the ICU proven or suspected infection as the main diagnosis.

    phase 3 small molecule active

    1 trial

  18. BGB-43395

    BEONE MEDICINES AUS PTY LTD

    HR+/HER2- Breast Cancer

    phase 3 small molecule active

    1 trial

  19. BGJ398

    BridgeBio Oncology Therapeutics

    Advanced Cholangiocarcinoma

    phase 3 small molecule terminated

    1 trial

  20. BI 1015550, BI 1015550

    Boehringer Ingelheim

    idiopathic pulmonary fibrosis (IPF), progressive pulmonary fibrosis (PPF)

    phase 3 small molecule active

    1 trial

  21. BI 1015550, Placebo matching BI 1015550, BI 1015550

    Boehringer Ingelheim

    Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)

    phase 3 small molecule active

    1 trial

  22. BI 1015550, Placebo matching nerandomilast (BI 1015550)

    Boehringer Ingelheim

    Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD)

    phase 3 small molecule active

    1 trial

  23. BI 10773

    Boehringer Ingelheim

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  24. BI 1291583

    Boehringer Ingelheim

    Bronchiectasis

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources